Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Increase in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXPGet Rating) was the recipient of a significant increase in short interest during the month of April. As of April 30th, there was short interest totalling 45,070,000 shares, an increase of 21.8% from the April 15th total of 37,000,000 shares. Based on an average daily trading volume, of 28,890,000 shares, the days-to-cover ratio is presently 1.6 days.

Shares of NASDAQ:TNXP traded down $0.06 during trading on Wednesday, reaching $2.15. 22,765 shares of the company traded hands, compared to its average volume of 18,954,112. The firm has a fifty day simple moving average of $0.23 and a 200 day simple moving average of $0.31. Tonix Pharmaceuticals has a 1-year low of $2.16 and a 1-year high of $45.44.

Tonix Pharmaceuticals (NASDAQ:TNXPGet Rating) last issued its earnings results on Monday, May 9th. The company reported ($1.60) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.60). Equities research analysts expect that Tonix Pharmaceuticals will post -0.2 earnings per share for the current fiscal year.

A number of equities analysts recently commented on the stock. Noble Financial assumed coverage on shares of Tonix Pharmaceuticals in a research note on Monday, April 18th. They issued an “outperform” rating and a $19.20 price objective for the company. StockNews.com assumed coverage on shares of Tonix Pharmaceuticals in a research note on Friday, May 13th. They issued a “sell” rating for the company.

Several large investors have recently modified their holdings of TNXP. Morgan Stanley lifted its stake in shares of Tonix Pharmaceuticals by 46,800.7% in the 1st quarter. Morgan Stanley now owns 282,342 shares of the company’s stock valued at $361,000 after purchasing an additional 281,740 shares during the last quarter. Royal Bank of Canada acquired a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at $25,000. Bank of America Corp DE lifted its stake in shares of Tonix Pharmaceuticals by 2,576,750.0% in the 2nd quarter. Bank of America Corp DE now owns 154,611 shares of the company’s stock valued at $171,000 after purchasing an additional 154,605 shares during the last quarter. Invesco Ltd. acquired a new stake in shares of Tonix Pharmaceuticals in the 2nd quarter valued at $95,000. Finally, SG Americas Securities LLC lifted its stake in shares of Tonix Pharmaceuticals by 1,670.2% in the 3rd quarter. SG Americas Securities LLC now owns 229,611 shares of the company’s stock valued at $138,000 after purchasing an additional 216,640 shares during the last quarter. 22.87% of the stock is owned by institutional investors.

About Tonix Pharmaceuticals (Get Rating)

Tonix Pharmaceuticals Holding Corp. discovers, acquires, develops, and licenses small molecules and biologics to treat and prevent human diseases and alleviate suffering. Its immunology product candidates include biologics to address organ transplant rejection, autoimmune diseases, and cancer; and central nervous system (CNS) product candidates comprise small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions.

Featured Stories

Receive News & Ratings for Tonix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.